Abstract 1301P
Background
CRT followed by adjuvant Durvalumab (D) is standard of care for fit patients (pts) with unresectable stage III NSCLC. However, most pts will not benefit from the CRT part of the treatment. We aimed to build a prognostic model to identify pts who may not benefit from CRT without D.
Methods
Pts with stage III NSCLC treated with curative intent CRT (platinum-doubled and chest RT to a dose of 60-66 Gy) were identified from the prospective biobank project (2003-2019; NCT01084785). No pts received immunotherapy or targeted agents, neither in the primary treatment, nor for recurrence. Clinical parameters included age, sex, performance status (PS), stage (UICC 8), BMI; circulating biomarkers were GM-CSF, IFNα2a, IFNy, IL-10, IL-12p70, IL-1β, IL-2, IL-6, IL-8, TNF-α, IFNβ, IL-1α, IP10, MCP1, PD-L1. Cut-off points were based on maximum Log-Rank statistic (with correction for multiple testing). Overall survival (OS) was calculated from start of RT. Significance level alpha was set at 0.05.
Results
342 pts were included: mean age 64.7 ± 9.4 yrs; 62.3 % male; PS 0: 36.3 %, 1: 50.8 %, 2 or more: 12.9 %; stage: IIIA: 42.7 %; IIIB: 45.0 %, IIIC: 12.3 %. Median follow-up was >10 years. Median OS was 1.8 years (95 % CI 1.46-2.20), the 1-, 2- and 5-year OS 65.8 %, 48.5 % and 27.5 %. In multivariate analysis, higher age (p=0.003), male gender (p=0.043), PS 2 or higher (p=0.036), stage IIIB (p=0.003) or stage IIIC (p<0.001), higher IL6 (p<0.001) and higher circulating PD-L1 (p=0.001) were significant for poorer OS. The best cut-offs for IL-6 and PD-L1 were 3.39 pg/ml and 155.52 pg/ml, respectively. The multivariate prognostic model had an AUC = 0.78 (95 % CI 0.73-0.84) for 1-year OS and 0.76 (0.71-0.81) for 2-year OS. Pts in the best prognostic group (below threshold for IL6 and PD-L1; 34.4 % of total) had a median OS of 44 months, in the intermediate group (above threshold for one biomarker; 41.8 % of total) a median OS of 20 months and in the worst group (both markers above threshold; 23.6 % of total) a median OS of 8 months.
Conclusions
This easy to apply multivariate model for OS, which includes IL6 and circulating PD-L1, may identify pts with a poor OS after standard CRT without immunotherapy. These pts may benefit from alternative treatments without platinum-based chemotherapy and RT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dirk De Ruysscher.
Funding
Maastro Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1265P - Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): A single-arm, phase II trial
Presenter: Shi Yan
Session: Poster session 04
1266P - Prediction of lung cancer risk in ground-glass nodules using deep learning from CT images
Presenter: Anil Vachani
Session: Poster session 04
1267P - Enhancing pulmonary nodule diagnosis: A combinatorial model of cfDNA methylation, plasma proteins and LDCT imaging
Presenter: Meng Yang
Session: Poster session 04
1268P - Liquid biopsy and CT-based multi-omics fusion enhances differential diagnosis of early-stage lung adenocarcinoma
Presenter: Yanwei Zhang
Session: Poster session 04
1269P - Machine learning model for predicting lung cancer recurrence after surgical treatment: A retrospective study using NLST and European hospital data
Presenter: Ann Valter
Session: Poster session 04
1272P - Postoperative survival prediction in non-small cell lung cancer patients based on driver genotypes
Presenter: Huiting Wang
Session: Poster session 04
1273P - The prognostic value evaluation of a tissue Comprehensive Genomic Profiling (CGP)-informed personalized MRD detection assay in NSCLC
Presenter: Wei Gao
Session: Poster session 04
1274P - Early dynamics of circulating tumor DNA following curative hypofractionated radiotherapy related to disease control in lung cancer
Presenter: Kyungmi Yang
Session: Poster session 04
1275P - Genomic analysis of lung adenocarcinoma with micropapillary component: Identification of micropapillary-related subtypes and development of a prognostic model
Presenter: Yuechun Lin
Session: Poster session 04